Yasuchika Hasegawa is Chairman of the Board of Takeda Pharmaceutical Company Ltd.  With a career at Takeda spanning 45 years, Mr. Hasegawa has been instrumental in transforming the company into a global pharmaceutical leader. Mr. Hasegawa became President in 2003 and Chief Executive Officer in 2009. During his tenure as President and CEO, he oversaw two key acquisitions for Takeda: the oncology company, Millennium Pharmaceuticals in 2008, and Swiss biotech Nycomed in 2011, which significantly increased the company’s global footprint.  Since joining Takeda in 1970, Mr. Hasegawa has served in roles of increasing responsibility. He spent three years in Germany and 10 years in the U.S., first as Vice President and then as President of TAP Pharmaceutical Products, Inc., a former joint venture between Takeda and Abbott. In addition to his extensive work at Takeda, Mr. Hasegawa has served as Chairman of the Keizai Doyukai (Japan Association of Corporate Executives), and as a member of the Abe government’s Industrial Competitiveness Council since 2013. He graduated from Waseda University in Japan.